The obtained results strongly suggest that the D16F7 mAb might be used as a therapeutic agent in metastatic melanoma as well as other tumors or pathological conditions in which VEGFR-1 ligands, such as VEGF-A and PlGF, are involved. This evidence concerns the gene VEGFA and metastatic melanoma.